Good Lifestyle

WhenPrescribed medications of our doctors, we do not normally think twice. Unfortunately, with any medicine, there are often risks that may not be entirely completed before years later, especially for people with certain conditions. The Food and Drug Administration (FDA) has now warned a medicine that can increase heart problems for those who take it. Read it to find out if you take this medicine, and for more FDA advice,The FDA has just released a new warning about these over-the-counter pain drugs.

The FDA has issued a declaration in February, warns the Americans that "preliminary result of an initial clinical security trial" on Xeljanz showed aIncreased risk of serious problems related to the heart Following the drug. This medicine, which is an arthritis and a ulcerative colitis classified under the generic name tofacitinib - has been compared by the administration to another type of drug called the tumor necrosis (TNF) inhibitor, which also deals with arthritis. According to the conclusions of the trial, Xeljanz also increases the risk of cancer of someone in relation to those treated with a TNF inhibitor. And for more drug concerns,If you take Tylenol with that, your liver is in danger, say experts.

Xeljanz was approved by the FDA in 2012 to treat rheumatoid arthritis in patients who did not respond well to another rheumatoid arthritis drug, methotrexate. In 2017, the FDA also approved Xeljanz to treat patients with psoriastic arthritis (PSA) that did not respond well to methotrexate or other similar drugs. Finally, in 2018, the FDA approved the drug to treat another condition called ulcerative colitis, a chronic inflammatory disease affecting the colon. "Tofacitinib works by reducing the activity of the immune system; a hyperactive immune system contributes to the RA, PSA and ulcerative colitis," said the FDA. And for more information up to date,Sign up for our daily newsletter.

In February 2019 and July 2019, the FDA warned that the temporary trial results showed an increased risk of blood clots and deaths of using Xeljanz at a higher dose (10 milligrams) twice a day. According toThe drug information page FDA, patients treated with Xeljanz are also at an "increased risk of developing serious infections that can lead to hospitalization or death". Reported infections include active tuberculosis, invasive fungal infections, as well as bacterial and viral infections. And for more medication warnings,The FDA has published a new warning about this TBT for sale pain.

Xeljanz was created by the company Pfizer, who reported that this medicine was theThe most prescribed Jak inhibitor To treat moderate to severe rheumatoid arthritis from May 2020. And starting in 2019, the Company reported that about 196,000 patients in the USAD had been treated for rheumatoid arthritis, psoriastic arthritis or ulcerative colitis. The help of Xeljanz.

Despite the warnings, the FDA asks that anyone prescribing Xeljanz does not stop taking it alone. "Patients should not stop taking the tofacitin without the first consultant with your health professionals, as may aggravate your condition," said the administration in their warning. "Talk to your health professionals if you have any questions or concerns."

However, if you experience the sudden shortness of breath, chest pain worsen with breathing, swelling of one leg or arm, leg pain or sensitivity, or red skin or discolored in the leg or painful or swollen arm, the FDA asks you to temporarily stop taking the tofacitin and immediately search for emergency medical care because they can be symptoms of a blood clot. And for more your heart health, If you see that on your skin, your risk of cardiac attack is higher, the study says .